Abdul Mannan on CVT risk with CHC: It is Not One-Size-Fits-All!
Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, shared on LinkedIn:
”CVT risk with CHC is not one-size-fits-all.
The type of progestin matters enormously (fourth-generation worst), and the multiplication of risk factors (family history, thrombophilia, obesity) creates scenarios with 200+ fold increased risk.
Most important clinical change:
- Take family history more seriously – it predicts risk independently of thrombophilia testing.
- And if you’re prescribing CHC, think twice about fourth-generation progestins.
The absolute risk remains low for most women, but for that high-risk subset (family history + thrombophilia), the numbers are sobering enough to have serious conversations about alternative contraception.”
Read the full article in JTH.
Article: The risk of cerebral vein thrombosis associated with different types of combined hormonal contraceptives: a case-control study
Authors: Maria Abbattista, Addolorata Truma, Ida Martinelli, Francesca Gianniello, Serena M. Passamonti, Marco Capecchi, Andrea Artoni, Flora Peyvandi, Paolo Bucciarelli
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek
-
Jan 9, 2026, 08:58Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management
-
Jan 9, 2026, 07:38Bartosz Hudzik on Subacute Coronary Occlusions: Navigating the Gray Zone in CAD Care
-
Jan 9, 2026, 07:27Gregory Piazza on The Role of D-Dimer in VTE Evaluation
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology
-
Jan 9, 2026, 06:12James Caldwell on The Hidden Culprit in Perimesencephalic SAH